Deep Dive Ticker Tape
Article published Mar 12, 2026. Prices below use latest available snapshots.
IQV Price Structure
Loading chart…
Loading timeframes…
Conviction: Medium Status: Watch — RSI 49.6, price $165.12, below SMA, continued selling pressure
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🟡 RSI 49.6 — neutral. Price $165.12, -3.8% today, -7.5% 7D, -2.2% 30D. SMA20 ~$170.51 — price -3.2% below SMA. Recovery stalling. |
| Moat | Wide (1B+ patient records, 90% of top pharma) |
| Key insight | IQV dropped from $170.93 (03/11) to $165.12 (-3.4%). RSI stabilized at 49.6 despite price falling — a slight positive divergence. But the continued selling (-7.5% 7D) is concerning. Price remains below SMA. The RSI 17 → 39 recovery from last week has stalled and partially reversed. Wide moat thesis intact but thesis needs price stabilization. |
Action Matrix
| Action | Level | Why |
|---|---|---|
| Current | 🔍 Watch | Selling pressure continues. Wait for stabilization above $165. |
| Entry Zone | $155 - $175 | Current $165.12 — IN ZONE |
| Stop-Loss | $134 (-19%) | Below April 2025 52-week low |
| Target | $210 (+27%) | Return to pre-selloff mean |
Extended analysis
Price Data
| Stock | Price | 1D | 7D | 30D | 3M | RSI | Status | Action |
|---|---|---|---|---|---|---|---|---|
| IQV | $165.12 | -3.8% | -7.5% | -2.2% | -25.7% | 50 | 🟡 Neutral | 🔍 Watch |
Price vs Last Deep Dive (03/11)
| Metric | 03/11 | 03/12 | Change |
|---|---|---|---|
| Price | $170.93 | $165.12 | -$5.81 (-3.4%) |
| RSI | 39.4 | 49.6 | +10.2 (divergence — RSI up, price down) |
| SMA20 | ~$171.65 | ~$170.51 | -$1.14 |
| vs SMA | -0.4% | -3.2% | Further below SMA |
Update from 03/11: Continued selling. Price dropped -3.4% while RSI paradoxically rose. RSI/price divergence worth watching — could signal sellers exhausted. But with -7.5% 7D and still below SMA, not yet time to commit. Wait for $165 to hold for multiple days.
Company Overview
One-Liner
IQVIA provides data analytics, technology solutions, and contract research services to the life sciences industry.
Competitive Moat
| Moat Type | Present? | Evidence |
|---|---|---|
| Network effects | 🟢 | More data from trials = better analytics |
| Switching costs | 🟢 | Multi-year contracts, deeply embedded platforms |
| Cost advantages | 🟢 | Scale across 100+ countries |
| Intangible assets | 🟢 | Proprietary datasets covering 1B+ patient records |
Moat Width: Wide
Bull Case
- Wide moat confirmed — 1B+ patient records, 90% of top pharma.
- RSI price divergence — RSI stabilizing while price falls may signal exhaustion.
- P/E ~13x forward vs 5Y avg ~25x — Near valuation floor.
- IN entry zone — $155-175.
Bear Case
- -3.8% today, -7.5% 7D — Continued aggressive selling.
- 3M -25.7% — Significant distance from highs.
- R&DS cancellation trend — CRO pipeline concerns.
- $13B debt — Refinancing cost risk.
- SMA declining — Trend not yet turned.
Research Log
| Date | Update |
|---|---|
| 2026-02-15 | Created. RSI 14 extreme. $162.31. Wide moat, fair value $210-$230. |
| 2026-02-22 | $165.62. RSI improved to 25.5 — stabilization. |
| 2026-02-26 | $162.31. RSI slipped to 17.4 (failed recovery). |
| 2026-03-10 | OHLC still stale. |
| 2026-03-11 | FRESH DATA. $170.93. RSI 39.4. Major recovery from 17.4. At SMA. Watch. |
| 2026-03-12 | Selling continues. $165.12 (-3.4%). RSI 49.6. RSI/price divergence. Still in zone. Watch. |
The Gold
Key Discoveries
| Discovery | Implication |
|---|---|
| RSI rising while price falls | Positive divergence — could signal selling exhaustion |
| Recovery from RSI 17 stalling | Bottom not yet confirmed despite RSI improvement |
| 3M -25.7% | Deep discount to any fair value estimate |
Open Questions
- Is R&DS cancellation trend worsening?
- What is the refinancing schedule for $13B debt?
- Will $165 hold as support?